Delivery Order SPE2DB22D2005-SPE2DB25FJSQ3
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,427.80 to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Ropivacaine 0.2% in 400 mg/200 ml vials. The contract represents a firm fixed-price delivery order with an ultimate completion date of April 22, 2025, and will be performed at the vendor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's continued capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 ml in 200 ml units, with a ceiling value of $2,147.31. This competitively awarded, firm fixed-price delivery order is set to be completed by September 19, 2025, with performance occurring at the vendor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- The Defense Logistics Agency awarded a $2,345.08 delivery order to AmerisourceBergen Drug Corp on May 22, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 mL in 200 mL quantities, with completion targeted for May 23, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, utilizing open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ropivacaine 0.2% in a 400 mg/200 ml dosage format. This firm fixed-price delivery order, valued at $2,818.62, represents a non-competitive set-aside procurement and is scheduled for completion by June 20, 2025, with performance taking place at the vendor's facility in Conshohocken, Pennsylvania. The award is issued as a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $3,235.22 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's pharmaceutical supply services to the federal government and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 ml in 200 ml quantities, with a firm fixed price ceiling value of $1,908.72. The contract, which is a non-set-aside competitive award with an ultimate completion date of June 6, 2025, is performed from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,342.70 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). This firm fixed price contract, issued on August 15, 2025, represents a competitively awarded procurement with no set-aside designation and an ultimate completion date of August 18, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Ropivacaine 0.5% 150 mg/30 mL in 30 mL quantities, with a ceiling value of $5,786.97. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of May 13, 2025, and no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL) with a ceiling value of $3,342.70 and an ultimate completion date of July 1, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which carries a total value of $999,999,999.00 and extends through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ropivacaine 0.2% in a 400 mg/200 mL formulation with a ceiling value of $1,192.95. The contract utilizes firm fixed-price pricing and carries a completion date of September 2, 2025. This non-set-aside delivery order is performed from the vendor's facility in Conshohocken, Pennsylvania, and represents a child contract issued under a larger vehicle. This delivery order is...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJSQ3Delivery Order
The Defense Logistics Agency awarded a $4,400.42 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL), a local anesthetic pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of August 27, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a broad range of pharmaceutical products and medical supplies to military and veteran healthcare systems globally. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse medical supply requirements across multiple therapeutic domains for defense and civilian federal agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 8/26/25 |